Henry J Jansen1, Gerald M M Vervoort2, Anton F J de Haan3, Paetrick M Netten4, Wim J de Grauw5, Cees J Tack2. 1. Department of Internal Medicine, Radboud University Nijmegen Medical Center, Nijmegen, the Netherlands h.jansen@jbz.nl. 2. Department of Internal Medicine, Radboud University Nijmegen Medical Center, Nijmegen, the Netherlands. 3. Biostatistics Group, Department for Health Evidence, Radboud University, Nijmegen, the Netherlands. 4. Department of Internal Medicine, Jeroen Bosch Hospital, 's-Hertogenbosch, the Netherlands. 5. Department of Primary and Community Care, Radboud University Nijmegen Medical Center, Nijmegen, the Netherlands Family Practice Berghem, Berghem, the Netherlands.
Abstract
OBJECTIVE: The determinants of insulin-associated weight gain in type 2 diabetes mellitus (T2DM) are partly unknown. Therefore, we conducted a prospective study to identify predictors of insulin-associated weight gain. RESEARCH DESIGN AND METHODS: In patients with T2DM, we assessed physical activity by accelerometry and measured diabetes-related distress by questionnaires before and 6 and 12 months after starting insulin therapy. Glycemic control (HbA1c) and insulin dose were monitored. RESULTS: After 12 months of insulin therapy, mean body weight had increased by 3.0 ± 2.5 kg (P < 0.001). The drop in HbA1c was correlated with insulin-associated weight gain. With the use of a multiple linear regression model, a cluster of variables was identified that significantly related to weight gain. Diabetes-related distress, initial insulin dose, and the increase of insulin dose during the course of the study as well as age appeared to be important predictors of weight gain after initiation of insulin therapy. Physical activity (measured as MET) decreased from 1.40 ± 0.04 at baseline to 1.32 ± 0.04 MET (P < 0.05) but was not significantly related to weight changes. CONCLUSIONS: Diabetes-related distress, initial and titration of insulin dose, and age all significantly predict insulin-associated weight gain. After the initiation of insulin therapy, physical activity decreased significantly, but this did not determine weight gain over the first 12 months. Our study findings may have clinical implications.
OBJECTIVE: The determinants of insulin-associated weight gain in type 2 diabetes mellitus (T2DM) are partly unknown. Therefore, we conducted a prospective study to identify predictors of insulin-associated weight gain. RESEARCH DESIGN AND METHODS: In patients with T2DM, we assessed physical activity by accelerometry and measured diabetes-related distress by questionnaires before and 6 and 12 months after starting insulin therapy. Glycemic control (HbA1c) and insulin dose were monitored. RESULTS: After 12 months of insulin therapy, mean body weight had increased by 3.0 ± 2.5 kg (P < 0.001). The drop in HbA1c was correlated with insulin-associated weight gain. With the use of a multiple linear regression model, a cluster of variables was identified that significantly related to weight gain. Diabetes-related distress, initial insulin dose, and the increase of insulin dose during the course of the study as well as age appeared to be important predictors of weight gain after initiation of insulin therapy. Physical activity (measured as MET) decreased from 1.40 ± 0.04 at baseline to 1.32 ± 0.04 MET (P < 0.05) but was not significantly related to weight changes. CONCLUSIONS:Diabetes-related distress, initial and titration of insulin dose, and age all significantly predict insulin-associated weight gain. After the initiation of insulin therapy, physical activity decreased significantly, but this did not determine weight gain over the first 12 months. Our study findings may have clinical implications.
Authors: Pedro Mezquita-Raya; Rebeca Reyes-Garcia; Oscar Moreno-Perez; Javier Escalada-San Martin; Miquel Ángel Rubio Herrera; Martin Lopez de la Torre Casares Journal: Diabetes Ther Date: 2015-06-09 Impact factor: 2.945
Authors: Tomasz Klupa; Michał Możdżan; Janina Kokoszka-Paszkot; Magdalena Kubik; Małgorzata Masierek; Margerita Czerwińska; Maciej T Małecki Journal: Int J Endocrinol Date: 2016-09-14 Impact factor: 3.257
Authors: Thomas Nyström; Johan Bodegard; David Nathanson; Marcus Thuresson; Anna Norhammar; Jan W Eriksson Journal: Diabetes Obes Metab Date: 2017-03-16 Impact factor: 6.577
Authors: Janna A van Diepen; Joris H Robben; Guido J Hooiveld; Claudia Carmone; Mohammad Alsady; Lily Boutens; Melissa Bekkenkamp-Grovenstein; Anneke Hijmans; Udo F H Engelke; Ron A Wevers; Mihai G Netea; Cees J Tack; Rinke Stienstra; Peter M T Deen Journal: Diabetologia Date: 2017-04-05 Impact factor: 10.122
Authors: Christina M Gant; Ijmke Mensink; S Heleen Binnenmars; Job A M van der Palen; Stephan J L Bakker; Gerjan Navis; Gozewijn D Laverman Journal: PLoS One Date: 2019-06-19 Impact factor: 3.240